Clinical trial
Use of Infliximab for the Treatment of Pemphigus Vulgaris
NCT00283712 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00283712 |
|---|---|
| Title | Use of Infliximab for the Treatment of Pemphigus Vulgaris |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Infliximab in Subjects With Pemphigus Vulgaris Receiving Prednisone |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Autoimmunity Centers of Excellence |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pemphigus |
| Intervention type | Drug, Other |
| Interventions | Infliximab, Placebo Comparator |
| Enrollment | 20 |
| Start date | Mar 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Mar 1, 2011 |
| First posted | Jan 30, 2006 |
| Last update posted | Dec 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: